|
Feb 7
|
Invitae hires advisers, considers bankruptcy: WSJ
|
|
Dec 22
|
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
|
|
Dec 5
|
Better Growth Stock: CRISPR Therapeutics vs. Invitae
|
|
Oct 25
|
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
|
|
Sep 4
|
Great week for Invitae Corporation (NYSE:NVTA) institutional investors after losing 65% over the previous year
|
|
Jul 21
|
Invitae (NVTA) Upgraded to Buy: Here's Why
|